Arialys Therapeutics

Arialys Therapeutics is a private biotechnology company dedicated to exploring scientific breakthroughs in the field of autoimmune neurology and developing novel precision medicines for autoimmune neuropsychiatric disorders. Our lead therapeutic candidate, ART5803, is currently under development for the treatment of anti-NMDA receptor encephalitis (ANRE), a life-threatening neurological disorder that causes severe psychosis. ART5803 also holds potential for the treatment of autoimmune dementia. The Arialys team brings decades of experience in identifying biomedical research innovations with the potential to address significant unmet medical needs and advancing novel therapies into clinical applications.